KROS
Keros
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 0
Sell signal 3
Bearish Engulfing
RSI Overbought
EPS Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About KROS
Keros Therapeutics, Inc.
A clinical-stage biopharmaceutical company that developing products for hematological and musculoskeletal disorders
Biological Technology
Invalid Date
04/08/2020
NASDAQ Stock Exchange
169
12-31
Common stock
1050 Waltham Street, Suite 302 02421, Lexington, Massachusetts
--
Keros Therapeutics, Inc., was originally incorporated under the laws of the State of Delaware in December 2015. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for patients with hematological and musculoskeletal diseases. The company is a leader in understanding the role of transforming growth factor-beta (a family of proteins), a major regulator of red blood cell and platelet production and muscle and bone growth, repair and maintenance.
Company Financials
EPS
KROS has released its 2024 Q4 earnings. EPS was reported at -1.14, versus the expected -0.43, missing expectations. The chart below visualizes how KROS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
KROS has released its 2024 Q4 earnings report, with revenue of 3.04M, reflecting a YoY change of 2027.27%, and net profit of -46.03M, showing a YoY change of -14.37%. The Sankey diagram below clearly presents KROS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
